Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone

Journal of Pharmacology and Experimental Therapeutics

Volumn 341, Issue 1, 2012, Pages 81-89

  Muly, E Chris ^a,b   Votaw, J R ^c   Ritchie, J ^b   Howell, L L ^b  

^a ATLANTA VA MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; FALLYPRIDE F 18; PALIPERIDONE; RISPERIDONE; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BASAL GANGLION; BRAIN REGION; CAUDATE NUCLEUS; CEREBELLUM; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG INFUSION; DRUG RECEPTOR BINDING; MACACA; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PUTAMEN; RECEPTOR OCCUPANCY; TEMPORAL CORTEX;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ISOXAZOLES; MACACA MULATTA; MALE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; PYRIMIDINES; RECEPTORS, DOPAMINE D2; RISPERIDONE;

EID: 84858688208     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.189076     Document Type: Article

References (61)

1. Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, Hwang DR, Keilp J, Kochan L, Van Heertum R, et al. (2002) Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 22:3708-3719. (Pubitemid 37465776)
2. Agid O, Mamo D, Ginovart N, Vitcu I, Wilson AA, Zipursky RB, and Kapur S (2007) Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response-a double- blind PET study in schizophrenia. Neuropsychopharmacology 32:1209-1215. (Pubitemid 46788848)
3. Arakawa R, Ito H, Takano A, Takahashi H, Morimoto T, Sassa T, Ohta K, Kato M, Okubo Y, and Suhara T (2008) Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl) 197:229-235.
4. Bernard V, Le Moine C, and Bloch B (1991) Striatal neurons express increased level of dopamine D2 receptor mRNA in response to haloperidol treatment: a quantitative in situ hybridization study. Neuroscience 45:117-126.
5. Bigliani V, Mulligan RS, Acton PD, Ohlsen RI, Pike VW, Ell PJ, Gacinovic S, Kerwin RW, and Pilowsky LS (2000) Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study. Psychopharmacology (Berl) 150:132-140. (Pubitemid 30429293)
6. Bressan RA, Erlandsson K, Jones HM, Mulligan RS, Ell PJ, and Pilowsky LS (2003) Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]- epidepride SPET study. J Clin Psychopharmacol 23:5-14. (Pubitemid 36164419)
7. Crespo-Facorro B, Paradiso S, Andreasen NC, O'Leary DS, Watkins GL, Ponto LL, and Hichwa RD (2001) Neural mechanisms of anhedonia in schizophrenia: a PET study of response to unpleasant and pleasant odors. JAMA 286:427-435. (Pubitemid 32681485)
8. Farde L, Nordström AL, Wiesel FA, Pauli S, Halldin C, and Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544.
9. Fishburn CS, David C, Carmon S, and Fuchs S (1994) The effect of haloperidol on D2 dopamine receptor subtype mRNA levels in the brain. FEBS Lett 339:63-66.
10. Florijn WJ, Tarazi FI, and Creese I (1997) Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs. J Pharmacol Exp Ther 280:561-569. (Pubitemid 27171313)
11. Gold JM, Waltz JA, Prentice KJ, Morris SE, and Heerey EA (2008) Reward processing in schizophrenia: a deficit in the representation of value. Schizophr Bull 34:835-847.
12. Goldman-Rakic PS (1999) The physiological approach: functional architecture of working memory and disordered cognition in schizophrenia. Biol Psychiatry 46: 650-661.
13. Graybiel AM, Aosaki T, Flaherty AW, and Kimura M (1994) The basal ganglia and adaptive motor control. Science 265:1826-1831. (Pubitemid 24324235)
14. Haber SN (2003) The primate basal ganglia: parallel and integrative networks. J Chem Neuroanat 26:317-330.
15. Hall H, Farde L, Halldin C, Hurd YL, Pauli S, and Sedvall G (1996) Autoradiographic localization of extrastriatal D2-dopamine receptors in the human brain using [125I]epidepride. Synapse 23:115-123.
16. Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, and Jonkman JH (1993) Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 54:257-268. (Pubitemid 23294526)
17. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
18. Ito H, Arakawa R, Takahashi H, Takano H, Okumura M, Otsuka T, Ikoma Y, Shidahara M, and Suhara T (2009) No regional difference in dopamine D2 receptor occupancy by the second-generation antipsychotic drug risperidone in humans: a positron emission tomography study. Int J Neuropsychopharmacol 12:667-675.
19. Joyce JN (2001) D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period. Synapse 40:137-144.
20. Joyce JN, Janowsky A, and Neve KA (1991) Characterization and distribution of [125I]epidepride binding to dopamine D2 receptors in basal ganglia and cortex of human brain. J Pharmacol Exp Ther 257:1253-1263.
21. Kapur S, Remington G, Jones C, Wilson A, DaSilva J, Houle S, and Zipursky R (1996) High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 153:948-950. (Pubitemid 26225470)
22. Kapur S, Zipursky R, Jones C, Remington G, and Houle S (2000) Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514-520. (Pubitemid 30191189)
23. Kegeles LS, Slifstein M, Frankle WG, Xu X, Hackett E, Bae SA, Gonzales R, Kim JH, Alvarez B, Gil R, et al. (2008) Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology 33:3111-3125.
24. Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, and Meltzer HY (2005) Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol. Neuropsychopharmacology 30:2283-2289. (Pubitemid 41643981)
25. Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, and Meltzer HY (2006) Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 31:1991-2001.
26. Kessler RM, Woodward ND, Riccardi P, Li R, Ansari MS, Anderson S, Dawant B, Zald D, and Meltzer HY (2009) Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol Psychiatry 65:1024-1031.
27. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, et al. (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drugfree schizophrenic subjects. Proc Natl Acad Sci U S A 93:9235-9240.
28. Lauer M, Senitz D, and Beckmann H (2001) Increased volume of the nucleus accumbens in schizophrenia. J Neural Transm 108:645-660. (Pubitemid 32662409)
29. Lewis DA, Pierri JN, Volk DW, Melchitzky DS, and Woo TU (1999) Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia. Biol Psychiatry 46:616-626. (Pubitemid 29401859)
30. Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, and Janssen PA (1988) Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247:661-670.
31. Lidow MS and Goldman-Rakic PS (1997) Differential regulation of D2 and D4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs. J Pharmacol Exp Ther 283:939-946. (Pubitemid 27514658)
32. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, and Alexoff DL (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16:834-840. (Pubitemid 26292051)
33. Meador-Woodruff JH, Damask SP, Wang J, Haroutunian V, Davis KL, and Watson SJ (1996) Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology 15:17-29. (Pubitemid 26233387)
34. Mukherjee J, Christian BT, Narayanan TK, Shi B, and Mantil J (2001) Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride. Neuropsychopharmacology 25:476-488. (Pubitemid 32830952)
35. Nord M and Farde L (2011) Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther 17:97-103.
36. Nordström AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, and Uppfeldt G (1993) Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33: 227-235. (Pubitemid 23091497)
37. Okubo Y, Olsson H, Ito H, Lofti M, Suhara T, Halldin C, and Farde L (1999) PET mapping of extrastriatal D2-like dopamine receptors in the human brain using an anatomic standardization technique and [11C]FLB 457. Neuroimage 10:666-674. (Pubitemid 30026760)
38. Paxinos G, Huang X-F, and Toga AW (2000) The Rhesus Monkey Brain in Stereotaxic Coordinates. Academic Press, San Diego.
39. Peters F, Perani D, Herholz K, Holthoff V, Beuthien-Baumann B, Sorbi S, Pupi A, Degueldre C, Lemaire C, Collette F, et al. (2006) Orbitofrontal dysfunction related to both apathy and disinhibition in frontotemporal dementia. Dement Geriatr Cogn Disord 21:373-379. (Pubitemid 43735682)
40. Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, Costa DC, and Kerwin RW (1997) Limbic selectivity of clozapine. Lancet 350:490-491.
41. Preuss TM (2007) Evolutionary specializations of primate brain systems, in Primate Origins and Adaptations (Ravoso MJ and Dagosto M eds) pp 625-675, Springer, New York.
42. Price MC and Hoffman DW (1997) Therapeutic drug monitoring of risperidone and 9-hydroxyrisperidone in serum with solid-phase extraction and high-performance liquid chromatography. Ther Drug Monit 19:333-337. (Pubitemid 28053490)
43. Remmerie BM, Sips LL, de Vries R, de Jong J, Schothuis AM, Hooijschuur EW, and van de Merbel NC (2003) Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 783:461-472. (Pubitemid 35447997)
44. Riedel M, Schwarz MJ, Strassnig M, Spellmann I, Müller-Arends A, Weber K, Zach J, Müller N, and Möller HJ (2005) Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci 255:261-268. (Pubitemid 41187035)
45. Sakai K, Gao XM, Hashimoto T, and Tamminga CA (2001) Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal ganglia- thalamocortical neural pathways. Synapse 39:152-160. (Pubitemid 32104020)
46. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, and Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124:57-73. (Pubitemid 26112775)
47. Seeman P, Chau-Wong M, Tedesco J, and Wong K (1975) Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci U S A 72:4376-4380.
48. Selemon LD, Rajkowska G, and Goldman-Rakic PS (1995) Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch Gen Psychiatry 52:805-818; discussion 819-820.
49. Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, Kapur S, Zipursky RB, Wilson AA, Christensen BK, et al. (2000) Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 152:174-180.
50. Spina E, Avenoso A, Facciolà G, Salemi M, Scordo MG, Ancione M, Madia AG, and Perucca E (2001) Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology (Berl) 153:238-243. (Pubitemid 32127893)
51. Stephenson CM, Bigliani V, Jones HM, Mulligan RS, Acton PD, Visvikis D, Ell PJ, Kerwin RW, and Pilowsky LS (2000) Striatal and extra-striatal D2/D3 dopamine receptor occupancy by quetiapine in vivo. [123I]-epidepride single photon emission tomography(SPET) study. Br J Psychiatry 177:408-415.
52. Strait KR, Orkin JL, Anderson DC, and Muly EC (2010) Chronic, constant-rate, gastric drug infusion in nontethered rhesus macaques (Macaca mulatta). J Am Assoc Lab Anim Sci 49:207-214.
53. 11C]FLB 457. Am J Psychiatry 158:926-930.
54. Tauscher J, Jones C, Remington G, Zipursky RB, and Kapur S (2002) Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 7:317-321. (Pubitemid 34280640)
55. Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, and Mamo DC (2011) Predicting dopamine D2 receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J Clin Psychopharmacol 31:318-325.
56. Vernaleken I, Fellows C, Janouschek H, Bröcheler A, Veselinovic T, Landvogt C, Boy C, Buchholz HG, Spreckelmeyer K, Bartenstein P, et al. (2008) Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone). J Clin Psychopharmacol 28:608-617.
57. Weinberger DR, Berman KF, and Zec RF (1986) Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia I. Regional cerebral blood flow evidence. Arch Gen Psychiatry 43:114-124. (Pubitemid 16163530)
58. Wu D, Otton SV, Morrow P, Inaba T, Kalow W, and Sellers EM (1993) Human hepatic cytochrome P450 2D6-like activity in nonhuman primates: catalytic characterization in vitro. J Pharmacol Exp Ther 266:715-719. (Pubitemid 23318682)
59. 2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry 179:503-508.
60. Yasuno F, Suhara T, Okubo Y, Sudo Y, Inoue M, Ichimiya T, and Tanada S (2001) Dose relationship of limbic-cortical D2-dopamine receptor occupancy with risperidone. Psychopharmacology (Berl) 154:112-114. (Pubitemid 32186522)
61. Zhu HJ, Wang JS, Markowitz JS, Donovan JL, Gibson BB, and DeVane CL (2007) Risperidone and paliperidone inhibit p-glycoprotein activity in vitro. Neuropsychopharmacology 32:757-764. (Pubitemid 46426181)